Research Article

A Randomized, Double-Masked, Active-Controlled, Crossover Phase III Equivalence Study of Generic Dorzolamide 2% versus Innovator Trusopt® Eye Drop Solution in Subjects with Open-Angle Glaucoma or Ocular Hypertension

Katharina Bell,1 Christina Korb,1 Christina Butsch,1 Bert Constantin Giers,1 Anna Beck,1 Alicja Strzalkowska,1 Christian Ruckes,2 Ulrike Klingberg,3 Norbert Pfeiffer,1 and Katrin Lorenz1

1Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany
2Interdisciplinary Center Clinical Trials Mainz, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany
3Alfred E. Tiefenbacher GmbH & Co. KG, Hamburg, Germany

Correspondence should be addressed to Christina Korb; christina.korb@unimedizin-mainz.de

Received 12 January 2022; Revised 13 June 2022; Accepted 28 June 2022; Published 20 July 2022

Academic Editor: Zeynep Alkin

Copyright © 2022 Katharina Bell et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The aim of this study was to demonstrate the equivalence of generic dorzolamide 2% eye drops solution versus the innovator formulation (Trusopt® eye drop solution) in patients with open-angle glaucoma or ocular hypertension. Methods. This prospective, monocentric, double-masked, active-controlled crossover phase III study included 32 patients. After washout, patients were randomized to reference product (Trusopt®) or test product (dorzolamide 2% eye drops, Rompharm Company SRL) for a 4-week period. Subsequent washout and crossover were performed. Drops were applied t.i.d. The primary efficacy endpoint was the difference in mean diurnal IOP. Goldmann applanation tonometry was performed at 8 am, 12 pm, and 4 pm at each visit, and safety was assessed by documentation of adverse events (AEs). Therapy adherence was documented by self-reporting and eye drop bottle weighing. An ANOVA with treatment, sequence, study period, and patient within the sequence as effects was performed and an additional post hoc ANCOVA including the baseline IOP was also performed. Results. 34 patients were randomized and analyzed in the safety population. The per-protocol population included 32 patients. According to the self-report, all patients were >80% compliant. Under the ANCOVA model, the 90% confidence interval for the average change of the IOP −0.27 mmHg (−1.17 mmHg–0.64 mmHg) is included by the acceptance range −1.5 mmHg to +1.5 mmHg after excluding 2 patients, which had falsely reported high therapy adherence. No clinically relevant difference was observed in frequency or severity of the AEs between both treatments. Conclusions. This study showed the equivalence of the tested generic dorzolamide 2% eye drops solution to the reference product Trusopt® eye drops solution. Trial Registration. This trial is registered with (Clinical-Trials.gov (identifier: NCT00878917) on April 9, 2009).

1. Background

Glaucoma is a leading cause of blindness and represents a group of ocular disorders characterized by progressive loss of retinal ganglion cells and their axons. This optic nerve degeneration results in gradual loss of visual field, which may ultimately lead to blindness [1–3]. The pathogenesis of glaucoma is partially understood. Elevated intraocular pressure (IOP) is the most relevant risk factor for disease development or progression and at this moment in time, in addition, represents the only clinically addressable factor [4–10]. This also is the case for patients suffering from normal-tension glaucoma (NTG), which shows glaucomatous optic nerve damage despite normal IOP [11].
Pharmacological treatment with topical hypotensive drugs is generally considered to be the first-line therapy for newly diagnosed glaucoma patients. In patients not sufficiently controlled with monotherapy, drugs with different mechanisms of action are combined to reach an additive effect [12]. Depending on the individual disease severity and the rate of progression, an individualized target IOP is evaluated for each patient, aiming to reach not only this target IOP with the maximum amount of safety and efficacy but also including economic consideration [13]. Several classes of IOP-lowering topical agents are available and first-choice treatments include prostaglandins, beta-blockers, adrenergic antagonists, and carbonic anhydrase inhibitors (CAIs) [14–19]. The first topical CAI available was dorzolamide which was approved by the FDA (New Drug Application (NDA): 020408) in 1994 [14]; however, a dose-response study was performed several years beforehand [20]. It was shown to be safe and effective as a primary therapy as well as in combination with other IOP-lowering eye drops [21,22]. Concerning the cost efficiency of glaucoma treatment with topical eye drops, generic medications often are taken into consideration, as these can be distributed at a much lower cost than the innovator preparation [23]. Although cost efficiency is a major benefit of generic drugs, special care must be taken concerning equal efficacy and equal risk profile of the generic drug. Bioequivalence studies prove equivalence in terms of efficacy and safety. Such clinical studies are not only crucial for the registration of these drugs but also provide and improve confidence of health professionals and patients when making use of generic drugs.

The aim of this study was to demonstrate the equivalence of generic dorzolamide 2% eye drops solution versus the innovator formulation (Trusopt® eye drops solution) in of generic dorzolamide 2% eye drops solution versus the innovator formulation. Clinical studies are not only crucial for the registration of these drugs but also provide and improve confidence of health professionals and patients when making use of generic drugs.

2. Methods

This prospective, monocentric, double-masked, active-controlled crossover phase III study was performed at the Department of Ophthalmology, University Medical Center, Johannes Gutenberg University of Mainz, Germany. Scientific advice by the competent authorities in Germany was obtained before the finalization of the study protocol as the aim of this study was the registration of generic dorzolamide 2% eye drops solution in a decentralized application. Approvals by the Ethics Committee of “Landesärztekammer Rheinland-Pfalz” (handling code 837.035.09 (6540)) and by the competent authority “Bundesinstitut für Arzneimittel und Medizinprodukte” (06/03/2009; handling code 61-3910-4035002) were obtained before the study was started. The clinical trial was registered at ClinicalTrials.gov (identifier: NCT00878917) before the first patient was screened. Before inclusion, informed consent was obtained from every patient. The study was performed following the tenets of the Declaration of Helsinki. According to the sample size calculation, thirty-two patients were required.

2.1. Inclusion and Exclusion Criteria. The inclusion and exclusion criteria are given in Table 1.

If both the eyes qualified, the eye with the higher IOP was chosen for evaluation or if IOP was the same for both the eyes, the eye with the worse visual acuity was selected.

2.2. Study Treatments. The inclusion criteria were not in accordance with the indications for treatment mentioned in the German summary of medicinal product characteristics ("Fachinformation") for Trusopt® Eye drops (TRUS-GPC-2006 11 08) due to the fact that Trusopt was used as monotherapy and not in combination with beta-blockers. In this study, we referred to the guidelines of the “European Glaucoma Society” [14]. The guidelines state that dorzolamide 2% eye drops are appropriate as the first-choice treatment for monotherapy of primary open-angle glaucoma.

2.2.1. Test Product. Dorzolamide 2% eye drops solution containing dorzolamide 20 mg/ml as hydrochloride eye drops solution (Rompharm Company SRL, Romania) was used. The final formula for dorzolamide 2% eye drops solution is given in Table 2.

2.2.2. Reference Therapy. Trusopt® eye drops solution (2%) containing dorzolamide 20 mg/ml as hydrochloride (Chibret Pharmazeutische GmbH, Germany) was used.

On each container, there was masked labeling; thus, the patient and the study personnel did not know which medicine the participant was taking. All study personnel and the investigators performing investigations and/or assessments during the trial days were masked to the study of medicine.

Each patient was randomized to one of two treatment sequences (n = 16 per group), either with the test (T) product for 4 weeks followed by the reference (R) product for 4 weeks or the reference product for 4 weeks followed by the test product for 4 weeks. Randomization was performed by staff of the trial center. The randomization list was kept in safe and confidential custody by persons who did not enroll or treat study patients. The randomization contained one randomization block of size 32 (16 patients per treatment sequence). No stratification was done. The clinical trial site received a set of sealed envelopes, one for each patient. Before the first treatment sequence was initiated, a washout was performed according to the washout scheme: miotics and oral/topical carbonic anhydrase inhibitors for 5 days,
alpha and alpha/beta-agonists for 14 days; and beta-agonists and prostaglandins for 28 days.

A one week washout was performed between both products. Patients received one drop three times a day (at 08.00, 15.00, and 22.00) for the duration of each treatment phase.

The primary efficacy endpoint was the difference in mean diurnal IOP from visit 1 to visit 2 and from visit 3 to visit 4 in the study eye (per-protocol population). Patients who discontinued study treatment because of lack of IOP-lowering efficacy had their last IOP observation carried forward in the per-protocol analysis. The safety analysis was based on an intent-to-treat dataset and included all patients who received study medication. The secondary efficacy parameter was the difference in diurnal IOPs at each individual time point from visit 1 to visit 2 and from visit 3 to visit 4. One eye per patient was considered in this trial.

Both the eyes were treated with study medication during the study if the other eye required treatment as well, but the second eye was not used as the study eye. Four visits as well as a screening visit were performed throughout the study. If the patient did not take any prior IOP-lowering medication, screening and baseline visits were performed on the same day. The washout phase before baseline and between the two treatment sequences (7 days) was kept as short as possible and according to the recommendations of the European Glaucoma Society: Terminology and Guidelines for Glaucoma [14]. This was a requirement by the ethics committee to minimize the risks for the study subjects. Table 3 provides the trial schedule. At the inclusion visit, the mode of administration of the test product and reference therapy was explained to each patient in detail. A follow-up booklet, in which the patient should report any deviations from the stipulated frequency of application, any problems of local tolerability, any adverse reactions, and any comments related to the study, was handed to each patient. At visits 1 and 3, the first application of study medication was at 16:00 and was performed by study personnel. Fifteen minutes after the first application, the patient was asked about any side effects. At the last visit, all the investigational medicinal products (full, half-used, or empty) had to be returned to the investigator. At each visit, any change in the frequency of administration of the test product was recorded in the CRF. This evaluation was based on the data recorded in the follow-up booklet given to each patient. As an additional measure of compliance, the bottles were weighed before distribution to and after recollecting from the patients.

| Table 1: Inclusion and exclusion criteria. |
|------------------------------------------------|
| **Inclusion criteria** | **Male/female, all races** |
| Age > 18 years | In one or both the eyes |
| Primary open-angle glaucoma, pseudoexfoliation glaucoma, pigment dispersion glaucoma, and ocular hypertension | IOP between 18 and 32 mmHg in one of the 3 measurements (in the eyes not included in the study (fellow eye); IOP must have been controllable on no pharmacologic treatment or on the study medicine only) |
| Baseline IOP after washout (study eye) | Best-corrected distance visual acuity 20/200 (Snellen equivalent) or better in the study eye |

**Exclusion criteria**

Patients presenting one of the following criteria were excluded from study enrollment.

- Chronic or recurrent inflammatory eye disease
- Ocular trauma within the past six months
- Current ocular infection, i.e., conjunctivitis or keratitis
- Any abnormality preventing reliable applanation tonometry
- Intraocular surgery or laser treatment within the past three months
- Inability to discontinue contact lens wear during the study
- Use of any systemic medication that would affect IOP with less than a 1-month stable dosing regimen before the screening visit
- Patient allergic to sulfonamides
- Severe renal dysfunction or hyperchloraeamic acidosis

| Table 2: Final formula for dorzolamide 2% eye drops solution. |
|---------------------------------------------------------------|
| **No.** | **Material** | **Amount** | **Function** |
| 1 | Dorzolamide hydrochloride (corresponding to dorzolamide) | 22.30 mg (20.0 mg) | Active substance |
| 2 | Hydroxyethyl cellulose | 1.00 mg | Viscosity-increasing agent |
| 3 | Citric acid monohydrate | 4.00 mg | Buffering agent |
| 4 | Sodium hydroxide | 2.26 mg | Buffering agent |
| 5 | Mannitol | 20.00 mg | Tonicity agent |
| 6 | Benzalkonium chloride | 0.075 mg | Antimicrobial preservative |
| 7 | Purified water | 1.0 mL | Vehicle |

For the innovator formula, no details are published and available.
any additional local treatment affects IOP. If the patient reported prohibited treatment, exclusion of the trial was discussed. Goldmann applanation tonometry was performed at 8:00, 12:00, and 16:00 (±1 h) at each visit. This was achieved by anesthetizing the eyes with a solution containing oxybuprocaine HCl 4mg and fluorescein sodium (Railorbin® eye drops, Alcon Pharma GmbH, Freiburg, Germany), and the Goldmann tonometer dial was set to 10mmHg. After blindly adjusting the dial until the inner edge of the fluorescein mires touched slightly, the investigator then recorded the IOP value, reset the tonometer to 10mmHg, and repeated the process. Right eyes were always measured before left eyes. The IOP values (rounded to the nearest whole number) at each time point were recorded as the mean of 2 measurements within 2mmHg or the mean of 3 measurements if the first 2 measurements differed by ≥3mmHg. The IOP(t) at single time points were reported as measured with one digit only. The averaged values \( \text{IOPav} = \frac{(\text{IOP}(8:00) + \text{IOP}(12:00) + \text{IOP}(16:00))}{3} \) were reported with 2 digits. All IOP measurements were performed by 1 of 3 experienced investigators, and the same tonometer was used on each patient at all visits. The calibration of the tonometer was checked once a month. Safety was assessed by documentation of adverse events (AEs) and serious adverse events (SAEs).

2.3. Statistical Methods. An average reduction of the IOP from the period baseline of \( \delta\text{IOPav} = 3.0 \text{mmHg} \) with an intrasubject variability of ±2mmHg was assumed with dorzolamide treatment. A difference of 1.5mmHg was considered as clinically not relevant and thus acceptable. Equivalence thus was accepted if the 90% confidence interval for the treatment difference \( \delta\text{IOPav} \) was included by an acceptance range of ±1.5mmHg, which additionally is in agreement with equivalence for IOP-lowering drugs necessary for the FDA [25]. Thirty-two patients were required to demonstrate equivalence with a power of 80% if the true difference between the formulations was zero.

The prespecified analysis was an ANOVA with treatment, sequence, study period, and patient within the sequence as effects. Model assumptions were checked by testing the residuals for nonnormality. Sequence and period effects were also investigated. For the difference, \( \delta\text{IOPav} = \delta\text{IOPav} \) reference parametric point estimators for the treatment differences and 90% confidence intervals were calculated. However, the analysis of the study data revealed a much higher intrasubject variability than anticipated, especially for the baseline IOP between the study periods. Therefore, a post hoc ANCOVA including the baseline IOP was performed in addition. The analysis was repeated also for the single time points 8:00, 12:00, and 16:00.

3. Results

Forty-two patients were screened in total, and 34 patients were enrolled and randomized for the trial (20 female and 14 male). The clinical part of the study was performed between 15 May 2009 (first screening examination) and 29 January 2010 (last patient’s last visit). Twenty female and 14 male patients were analyzed in the safety population (Figure 1). The mean age of the safety population was 65.1 (range 47–83) years for females and 67.6 (range 59–74) years for male patients. All patients were Caucasians. Two patients dropped out during the study; therefore, the per-protocol population included 32 patients and the safety population included all 34 patients, as shown in Figure 1.
Forty-two patients were screened, of which 8 patients were not included in the study due to screening failure. Patients were randomized to either the first test and second reference product or first reference and second test product. 2 patients dropped out during the trial (1 in each sequence). 32 patients completed the trial. 26 adverse events were reported when test product was applied, and 21 adverse events were reported during reference product usage.

The primary efficacy parameter was the difference in mean diurnal IOP from visit 1 (baseline) to visit 2 and from visit 3 (baseline) to visit 4. The ANOVA and ANCOVA residuals were normally distributed, and there was no significant period and no sequence effect suggesting a carry-over effect. Using the ANOVA model anticipated in the statistical analysis plan, the 90% confidence interval for the primary endpoint the δIOPav difference (−0.53 mmHg (~1.58 mmHg–0.52 mmHg)) appeared to miss the anticipated acceptance range for equivalence of ±1.5 mmHg. According to the self-report in the patient booklet, all 32 patients were >80% compliant. After the closure of the database and analysis of the primary endpoint, the compliance was rechecked. It became obvious that the weight of the bottle containers and the self-reported entries in the patient booklets were not conformative. Two patients reported more than 80% compliance, but according to the weight of their bottles, we concluded that they could not have used more than 50% of their eye drops solution. The two subjects who should have been excluded due to compliance issues had a remarkable effect on the analysis of equivalence (see the extent of exposure). An analysis without these two patients revealed equivalence of both tested formulations.

The premedication baseline in each period is a significant (p value<0.01) source of variation in the ANCOVA model using the baseline IOP as a covariate. In the ANCOVA model, the intrasubject variability could be reduced to ±2.1 mmHg from ±2.48 mmHg of the model without covariate and the differences between the treatments were halved to ~0.27 mmHg. Under the ANCOVA model, the 90% confidence interval for the average change of the IOP −0.27 mmHg (~1.17 mmHg–0.64 mmHg) is included by the acceptance range −1.5 mmHg to +1.5 mmHg as stipulated in the study protocol. The same is true for the changes of the IOP at discrete time points, which all meet the acceptance range. There was no statistically significant difference in IOP at each time point at 8:00, 12:00, and 16:00 between the two drugs. Even the 95% confidence interval (~1.36 mmHg–0.82 mmHg) was in the acceptance range.

Similar relationships for the average IOP change (δIOPav) could be demonstrated also for the changes at discrete time points. The respective regression coefficients were 0.8537, 0.7071, and 0.830 for δIOP8:00, δIOP12:00, and δIOP16:00, respectively. The summary statistics for the average IOP in the study eye are given in Table 4.

All 34 patients treated with study medication were included in the safety evaluation. One drop-out patient only received the test product and the other only the reference therapy. Total individual drug exposure of the 32 patients who were dosed according to protocol differed between 2.37 g and 11.7 g of reference therapy and 2.61 – 11.59 g of test product during the study. 4 patients treated only one eye, which explains the lower consumption of medication in these patients. Only after the closure of the database and after unmasking, it became apparent that in 2 patients, both the eyes had been treated, which had been wrongly interpreted by the data management. The patients therefore could have used only about 50%–60% of the expected amount of study medication. It appeared illegitimate to revise the decision made in the data review meeting and to include these patients into the per-protocol population, after unmasking. Adverse events (AEs) during this study were evaluated as a secondary parameter. A detailed list of the AEs can be found in the supplementary Table 1.

Twenty-six of the 34 patients treated reported altogether 54 AEs: 26 AEs were reported by 18 patients after the administration of the test product and 21 AEs were reported by 13 patients after reference therapy, respectively. The reported AEs were eye disorders (12 patients), gastrointestinal disorders (5 patients), nervous system disorders (5 patients), injury, poisoning and procedural complications (4 patients), musculoskeletal and connective tissue disorders (4 patients), general disorders and administration site conditions (3 patients), and respiratory, thoracic, and mediastinal disorders (3 patients). Ear and labyrinth disorders, infections and infestations, investigations, psychiatric disorders, and skin and subcutaneous tissue disorders occurred only in one patient consecutively. Thirty-seven events were resolved completely. In 10 AEs, the outcome improved; in 4 cases, the outcome was unchanged, and in 2 cases, it is unknown.
manufactured by Rompharm Company SRL, Romania) (test product) is equivalent to that of Trusopt® eye drops solution (2%) applied t.i.d. (containing dorzolamide 20 mg/ml as hydrochloride, manufactured by Chibret Pharmazeutische GmbH, Germany) in patients with open-angle glaucoma or ocular hypertension.

The tested eye drop solution is designed as a generic drug for use on the European market. The European Medicine Agency (EMA) defines a generic drug as being of the same active substance as the already authorized reference medicine; however, inactive ingredients can differ. As studies showing the safety and efficacy of the reference product have already been performed, merely the quality of the medicine and the equivalent bioavailability had to be demonstrated (EMA/393905/2006 Rev. 2). As the tested solution shows a different viscosity to the reference product, a clinical trial showing equivalence of IOP-lowering properties was necessary. The standard study design for a generic medicine for the EMA is a randomized, two-period, two-sequence, single-dose crossover design, as performed here in this trial [26]. Equivalence was not reached in this trial. \( \delta \text{IOP}_{av} \) difference (\(-0.53 \text{ mmHg} \) to \(-1.58 \text{ mmHg} \) to \(-0.52 \text{ mmHg} \)) just failed to meet the equivalence bounds. However, for the following reasons, the competent authorities still accepted the data of this trial for registration of generic dorzolamide.

The study was conducted in adherence to the study protocol in compliance with GCP (Good Clinical Practice). In the unblinded data review phone conference, the study team agreed that there were no major protocol deviations likely to impair the evaluation of the study’s endpoints for the 32 patients that finished both study periods according to the protocol. Only after the closure of the database and unmasking the data, it became apparent that severe compliance issues had occurred in two patients. These two patients had treated both the eyes instead of one eye as misleadingly reported in the case report forms. The weight of the corresponding study medication containers revealed maximum compliance of 50–60%, which was in contrast to reported compliance of more than 80% in the patient diaries. This led to the conclusion that these two patients should have been excluded from the analysis due to insufficient compliance.

Insufficient adherence to medication is known to be a general problem in glaucoma patients and can lead to increased visual field progression [27]. A wide range of rates of compliance varying from 5% to 80% has been reported [28]. This is not only challenging for clinical trials but also in an everyday clinical setting, evaluating glaucoma progression despite good IOP values challenging for the treating physician [29]. A possible white-coat phenomenon leading to regular treatment usage approximately 5 days before seeing a specialist decreases the likelihood of detecting nonadherent patients [30]. A recent study analyzing reasons for non-adherence in long-term glaucoma patients demonstrated complete medication adherence of just about 41% of the patients, whereas the majority of the patients presented with moderate compliance (54%) [31]. The necessity of having to take a pill or apply the drop t.i.d. can also reduce patient compliance [32] and as being a chronic disease, causing no

### 4. Discussion

This monocentric randomized double-masked active-controlled clinical trial with a crossover design was performed to demonstrate the IOP-lowering efficacy of generic dorzolamide 2% eye drops solution applied three times a day (t.i.d) (containing dorzolamide 20 mg/ml as hydrochloride,
pain, adherence especially in not sight-threatening glaucoma is known to be low [33]. Experiencing side effects such as those reported within this trial can also limit patient adherence [33]. No clinically relevant differences in incidence or pattern of AEs were found between the two treatments investigated, although slightly more incidences were reported after using the test product. This could be due to the more gelatinous texture of the test solution, which possibly can lead to an extended exposure time on the ocular surface and might cause more side effects. Altogether, 53 adverse events (AEs) were observed during the study; in 30 of these AEs, the relationship was assessed as suspected (related, probably related, or possibly related) to the study drugs: 15 AEs occurred after administration of test medication and 15 AEs were documented while patients were on reference treatment. The most frequent AEs were eye disorders, followed by dysgeusia, dry mouth, and other common side effects of dorzolamide that were already described in the German summary of medicinal product characteristics. As performed in this trial, self-reported adherence can result in overestimation of patient compliance [29]; therefore, additional eye drop weighting was performed in this study. Although these additional measurements may not be valid to detect moderately non-compliant patients, we were able to identify participants with very low compliance. Weight variations were possible as patients were encouraged to try and instill another drop in case the first attempt missed the eye, until making sure the drop reached the eye. Elimination of the two severely non-compliant patients from the analysis was able to reveal the actual equivalence of the generic test product to the reference product received registration in 11 European countries in a decentralized procedure. In addition, this clinical trial shows that special precautions should be taken to determine patient adherence to the study medication. This could not only prevent potential drugs from reaching the market but is also relevant for companies investing in expensive clinical trials.

When comparing the IOP decreasing effects of the test vs. the reference product, a high variability was found. Introducing the premedication baseline IOP (at visits 1 and 3, respectively) as a covariate into the ANCOVA model led to reduction of the intrasubject variability from ±2.48 mmHg without covariate to ±2.11 mmHg. The consideration of the covariate in the model reduced not only the variability but also adjusted the Apriori differences of the baseline IOP between the two treatment groups (T: 20.01 mmHg, R: 20.35 mmHg). Under the ANCOVA model, the 90% confidence interval for the average change of the IOP became −0.27 mmHg (−1.17 mmHg–0.64 mmHg). This is within the acceptance range of −1.5 mmHg to +1.5 mmHg stipulated in the study protocol. The ANCOVA model substantially improved the precision of the analysis. These results suggest equivalence for the tested formulations with respect to the extent of the IOP decrease.

Another reason for the higher variability of the IOP decreasing effects could have been the fact that different investigators had determined the IOP in a patient at different visits or even at the same visit but at different time points. The intra and intersubject variabilities in Goldmann applanation tonometry are well known [34] and possibly could play a role, although the examiners all were trained and experienced. Cycloplegic drugs, in this study for dilated fundus examination at the screening visit and visit 4 as a safety parameter, can also cause a significant rise in IOP in patients with open-angle glaucoma [35].

5. Conclusions

This study showed the equivalence of the tested generic dorzolamide (dorzolamide 2% eye drops solution, containing dorzolamide 20 mg/ml as hydrochloride, manufactured by Rompharm Company SRL, Romania) to the reference product Trusopt® eye drops solution (2%) containing dorzolamide 20 mg/ml as hydrochloride (Chibret Pharmazeutische GmbH, Germany). Therefore, the tested product received registration in 11 European countries in a decentralized procedure. In addition, this clinical trial shows that special precautions should be taken to determine patient adherence to the study medication. This could not only prevent potential drugs from reaching the market but is also relevant for companies investing in expensive clinical trials.

Data Availability

The datasets during and/or analyzed during the current study are available from the corresponding author upon request.

| Country                  | Trade name                  |
|--------------------------|-----------------------------|
| Hungary, Latvia, Poland, Slovakia | Latalux                     |
| Germany, Austria, Denmark, Finland, Norway, Sweden | Dorzolamide Tiefenbacher |
| France                   | Dorzolamide Alfred E. Tiefenbacher |
| Germany, Denmark, Norway, Sweden | Dorat 20 mg/ml |
| Germany, France          | Zolasopt 20 mg/ml           |
Ethical Approval

Approvals by the Ethics Committee of “Landesärztekammer Rheinland-Pfalz” (handling code 837.035.09 (6540)) and by the competent authority “Bundesinstitut für Arzneimittel und Medizinprodukte” (06/03/2009; handling code 61-3910-4035002) were obtained before the study was started.

Consent

All patients signed a patient informed consent form before they were included in this trial.

Conflicts of Interest

Ulrike Klingberg is an employee of the sponsor of the study. The other authors declare that they have no conflicts of interest.

Authors’ Contributions

Norbert Pfeiffer, Katrin Lorenz, Christina Korb, and Christian Ruckes conceptualized and designed the study. Norbert Pfeiffer, Katrin Lorenz, Christina Korb, Christina Butsch, Anna Beck, and Christian Ruckes collected and analyzed data. Katrin Lorenz and Katharina Bell wrote the first draft of the manuscript. All authors commented on previous versions of the manuscript, revised them critically, and approved the final manuscript.

Acknowledgments

The trial was sponsored by Alfred E. Tiefenbacher GmbH & Co. KG. The authors acknowledge that the sponsor paid financial compensation to the Department of Ophthalmology and Interdisciplinary Center Clinical Trials Mainz for conducting the clinical trial.

Supplementary Materials

Supplementary Table 1 provides the number and percent of patients reporting adverse events, by system organ class, preferred term, and treatment. (Supplementary Materials)

References

[1] H. A. Quigley, “Open-angle glaucoma,” New England Journal of Medicine, vol. 328, no. 15, pp. 1097–1106, 1993.
[2] H. A. Quigley, “Number of people with glaucoma worldwide,” British Journal of Ophthalmology, vol. 80, no. 5, pp. 389–393, 1996.
[3] C. Cedrone, C. Nucci, G. Scuderi, F. Ricci, A. Cerulli, and F. Culasso, “Prevalence of blindness and low vision in an Italian population: a comparison with other European studies,” Eye, vol. 20, no. 6, pp. 661–667, 2006.
[4] The Advanced Glaucoma Intervention Study, “The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators,” American Journal of Ophthalmology, vol. 130, no. 4, pp. 429–440, 2000.
[5] L. K. Mao, W. C. Stewart, and M. B. Shields, “Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma,” American Journal of Ophthalmology, vol. 111, no. 1, pp. 51–55, 1991.
[6] A. Heijl, M. C. Leske, B. Bengtsson, L. Hyman, and M. Hussein, “Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial,” Archives of Ophthalmology, vol. 120, no. 10, p. 1268, 2002.
[7] M. A. Kass, D. K. Heuer, E. J. Higginbotham et al., “The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma,” Archives of Ophthalmology, vol. 120, no. 6, p. 701, 2002.
[8] P. R. Lichter, D. C. Musch, B. W. Gillespie et al., “Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery,” Ophthalmology, vol. 108, no. 11, pp. 1943–1953, 2001.
[9] “The glaucoma laser trial (GLT): 6. Treatment group differences in visual field changes. Glaucoma laser trial research group,” American Journal of Ophthalmology, vol. 120, no. 1, pp. 10–22, 1995.
[10] D. Gherghel, S. Orgul, K. Gugleta, M. Gekkieva, and J. Flammer, “Relationship between ocular perfusion pressure and retrobulbar blood flow in patients with glaucoma with progressive damage,” American Journal of Ophthalmology, vol. 130, no. 5, pp. 597–605, 2000.
[11] M. C. Leske, “Open-angle glaucoma—an epidemiologic overview,” Ophthalimc Epidemiology, vol. 14, no. 4, pp. 166–172, 2007.
[12] N. Pfeiffer and The TATS Travatan Adjunctive Treatment Study group, “Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension,” Graefes Archive for Clinical and Experimental Ophthalmology, vol. 249, no. 7, pp. 1065–1071, 2011.
[13] H. Bagga, J. H. Liu, and R. N. Weinreb, “Intraocular pressure measurements throughout the 24 h,” Current Opinion in Ophthalmology, vol. 20, no. 2, pp. 79–83, 2009.
[14] European Glaucoma Society, Terminology and Guidelines for Glaucoma, Dogma, Savona, Italy, 2008.
[15] D. A. Lee and E. J. Higginbotham, “Glaucoma and its treatment: a review,” American Journal of Health-System Pharmacy, vol. 62, no. 7, pp. 691–699, 2005.
[16] C. Y. H. Hu, H. Matsuo, G. Tomita et al., “Clinical characteristics and leakage of functioning blebs after trabeculectomy with mitomycin-C in primary glaucoma patients,” Ophthalmology, vol. 110, no. 2, pp. 345–352, 2003.
[17] R. L. Stamper, S. A. Wigginton, and E. J. Higginbotham, “Primary drug treatment for glaucoma: beta-blockers versus other medications,” Survey of Ophthalmology, vol. 47, no. 1, pp. 63–67, 2002.
[18] R. L. Radius, “Use of betaxolol in the reduction of elevated intraocular pressure,” Archives of Ophthalmology, vol. 101, no. 6, pp. 898–900, 1983.
[19] S. M. Drance and P. A. Nash, “The dose response of human intracocular pressure to pilocarpine,” Canadian Journal of Ophthalmology, vol. 6, no. 1, pp. 9–13, 1971.
[20] E. A. Lippa, L. E. Carlson, B. Ehinger et al., “Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor,” Archives of Ophthalmology, vol. 110, no. 4, p. 495, 1992.
[21] E. Strahlman, R. Tipping, and R. Vogel, “A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response...
Study Group," American Journal of Ophthalmology, vol. 122, no. 2, pp. 183–194, 1996.

[22] E. Strahlman, R. Tipping, and R. Vogel, "A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol," Archives of Ophthalmology, vol. 113, no. 8, p. 1009, 1995.

[23] M. B. Schlenker, G. E. Trope, and Y. M. Buys, "Comparison of United States and Canadian glaucoma medication costs and price change from 2006 to 2013," Journal of Ophthalmology, vol. 2015, Article ID 547960, 8 pages, 2015.

[24] R. Alfonso-Cristancho, T. Anda, T. Barbosa, and J. H. Watanabe, "Definition and classification of generic drugs across the world," Applied Health Economics and Health Policy, vol. 13, no. S1, pp. S5–S11, 2015.

[25] R. N. Weinreb and P. L. Kaufman, "The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium," Investigative Ophthalmology & Visual Science, vol. 50, no. 4, p. 1497, 2009.

[26] N. Refalo, D. Chetcuti, A. Tanti, A. Serracino-Inglott, and J. J. Borg, "Changing paradigms in bioequivalence trials submitted to the EMA for evaluation—a clinical and regulatory perspective," Saudi Pharmaceutical Journal: SPJ, vol. 25, no. 2, pp. 280–289, 2017.

[27] P. A. Newman-Casey, L. M. Nizioł, B. W. Gillespie, N. K. Janz, P. R. Lichter, and D. C. Musch, "The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study," Ophthalmology, vol. 127, no. 4, pp. 477–483, 2020.

[28] C. M. Olthoff, J. S. Schouten, B. W. van de Borne, and C. A. Webers, "Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review," Ophthalmology, vol. 112, no. 6, pp. 953–961, 2005.

[29] C. O. Okeke, H. A. Quigley, H. D. Jampel et al., "Adherence with topical glaucoma medication monitored electronically," Ophthalmology, vol. 116, no. 2, pp. 191–199, 2009.

[30] G. F. Schwartz and H. A. Quigley, "Adherence and persistence with glaucoma therapy," Survey of Ophthalmology, vol. 53, no. 6, pp. S57–S68, 2008.

[31] J. F. McClelland, L. Bodle, and J. A. Little, "Investigation of medication adherence and reasons for poor adherence in patients on long-term glaucoma treatment regimes," Patient Preference and Adherence, vol. 13, pp. 431–439, 2019.

[32] M. T. Brown and J. K. Bussell, "Medication adherence: WHO cares?" Mayo Clinic Proceedings, vol. 86, no. 4, pp. 304–314, 2011.

[33] F. Meier-Gibbons and M. Toteberg-Harms, "Influence of cost of care and adherence in glaucoma management: an update," Journal of Ophthalmology, vol. 2020, Article ID 5901537, 5 pages, 2020.

[34] M. M. Whitacre and R. Stein, "Sources of error with use of Goldmann-type tonometers," Survey of Ophthalmology, vol. 38, no. 1, pp. 1–30, 1993.

[35] B. R. Shaw and R. A. Lewis, "Intraocular pressure elevation after pupillary dilation in open angle glaucoma," Archives of Ophthalmology, vol. 104, no. 8, pp. 1185–1188, 1986.